Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0360220230640100930
Journal of the Korean Ophthalmological Society
2023 Volume.64 No. 10 p.930 ~ p.938
Latanoprostene Bunod 0.024% w/v Treatment of Open-anlge Glaucoma: Short-term Effects, Safety, and Changes in Ocular Blood Flow
Kim Hyun-Woo

Nam Seok-Jin
Seo Sam
Lee Kyoo-Won
Lee Chang-Hoon
Abstract
Purpose: To study the short-term intraocular pressure (IOP)-lowering effect and optic nerve head (ONH) blood flow improvement after switching from latanoprost 0.005% w/v to latanoprostene bunod 0.024% w/v.

Methods: This prospective study ran from May 2022 to December 2022 and included 40 patients with open-angle glaucoma who switched from latanoprost 0.005% w/v to latanoprostene bunod 0.024% w/v. The IOP, ONH blood flow, and conjunctival hyperemia, corneal erosion, and eyelid pigmentation status were measured 3 months after switching. We recorded all possible side effects.

Results: The baseline IOP significantly dropped from 17.53 ¡¾ 6.49 to 16.00 ¡¾ 8.06 mmHg at 3 months (p = 0.032). The best-corrected visual acuity did not significantly change (0.24 ¡¾ 0.19 to 0.23 ¡¾ 0.16); neither did eyelid pigmentation (1.16 ¡¾ 0.78 to 1.16 ¡¾ 0.82) nor the corneal erosion score (0.58 ¡¾ 0.85 to 0.39 ¡¾ 0.76). Conjunctival hyperemia significantly decreased from 2.00 ¡¾ 0.69 to 1.67 ¡¾ 0.63 (p = 0.010). Neither the whole-image vessel density nor the peripapillary vessel density significantly changed.
However, pruritus became significantly worse after the change (p = 0.008).

Conclusions: In the short term, latanoprostene bunod 0.024% w/v lowered the IOP more effectively than did latanoprost 0.005% w/v. However, there was no significant change in ONH blood flow after the switch.
KEYWORD
Intraocular pressure, Latanoprostene bunod, Ocular blood flow, Open angle glaucoma
FullTexts / Linksout information
 
Listed journal information